These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18224458)

  • 1. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy.
    Park SH; Cho MS; Kim YS; Hong J; Nam E; Park J; Cho EK; Shin DB; Lee JH; Lee WK
    Qual Life Res; 2008 Mar; 17(2):207-14. PubMed ID: 18224458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
    Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
    J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.
    Kim JW; Kim JG; Kang BW; Chung IJ; Hong YS; Kim TY; Song HS; Lee KH; Zang DY; Ko YH; Song EK; Baek JH; Koo DH; Oh SY; Cho H; Lee KW
    Cancer Res Treat; 2019 Jan; 51(1):223-239. PubMed ID: 30584995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
    Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
    J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Stenholm L; Stoehlmacher-Williams J; Al-Batran SE; Heussen N; Akin S; Pauligk C; Lehmann S; Senff T; Hofheinz RD; Ehninger G; Kramer M; Goekkurt E
    Ann Oncol; 2013 Oct; 24(10):2581-2588. PubMed ID: 23975664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
    Chau I; Norman AR; Cunningham D; Waters JS; Oates J; Ross PJ
    J Clin Oncol; 2004 Jun; 22(12):2395-403. PubMed ID: 15197201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline quality of life predicts overall survival in patients with mCRPC treated with
    Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
    Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
    Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
    Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
    Luoma ML; Hakamies-Blomqvist L; Sjöström J; Pluzanska A; Ottoson S; Mouridsen H; Bengtsson NO; Bergh J; Malmström P; Valvere V; Tennvall L; Blomqvist C
    Eur J Cancer; 2003 Jul; 39(10):1370-6. PubMed ID: 12826039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline quality of life predicts survival in patients with advanced colorectal cancer.
    Maisey NR; Norman A; Watson M; Allen MJ; Hill ME; Cunningham D
    Eur J Cancer; 2002 Jul; 38(10):1351-7. PubMed ID: 12091066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline functioning scales of EORTC QLQ-C30 predict overall survival in patients with gastrointestinal cancer: a meta-analysis.
    Zang Y; Qiu Y; Sun Y; Fan Y
    Qual Life Res; 2024 Jun; 33(6):1455-1468. PubMed ID: 38227073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma.
    Yeo W; Mo FK; Koh J; Chan AT; Leung T; Hui P; Chan L; Tang A; Lee JJ; Mok TS; Lai PB; Johnson PJ; Zee B
    Ann Oncol; 2006 Jul; 17(7):1083-9. PubMed ID: 16600982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
    Efficace F; Bottomley A; Coens C; Van Steen K; Conroy T; Schöffski P; Schmoll H; Van Cutsem E; Köhne CH
    Eur J Cancer; 2006 Jan; 42(1):42-9. PubMed ID: 16298522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
    Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
    Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
    el Aziz LM
    Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.
    Fanotto V; Cordio S; Pasquini G; Fontanella C; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Torri V; Aprile G
    Gastric Cancer; 2017 Sep; 20(5):825-833. PubMed ID: 28028664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
    Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
    Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.